Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 32-37

  Ma, Hongxia ^a   Chen, Jiaping ^a   Pan, Shiyang ^b   Dai, Juncheng ^a   Jin, Guangfu ^a   Hu, Zhibin ^a   Shen, Hongbing ^a,b   Shu, Yongqian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Molecular epidemiology; NSCLC; Polymorphism; Survival

Indexed keywords

CYCLIN A1; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 7; CYCLIN E; CYCLIN H; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P19; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE; CHINESE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CCN INTERCELLULAR SIGNALING PROTEINS; CYCLIN-DEPENDENT KINASES; FEMALE; GENES, CDC; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 79957753124     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.11.001     Document Type: Article

References (51)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics 2006. CA Cancer J Clin 2006, 56:106-130.
4. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001, 71:1759-1764.
5. Scott A., Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med 2008, 2:577-586.
6. Marijon H., Bouyon A., Vignot S., Besse B. Prognostic and predictive factors in lung cancer. Bull Cancer 2009, 96:391-404.
7. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005, 11:3974-3986.
8. McDonald E.R., El-Deiry W.S. Cell cycle control as a basis for cancer drug development (review). Int J Oncol 2000, 16:871-886.
9. Norbury C., Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992, 61:441-470.
10. Goode E.L., Fridley B.L., Vierkant R.A., Cunningham J.M., Phelan C.M., Anderson S., et al. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18:935-944.
11. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36:131-149.
12. Pines J. Cyclins: wheels within wheels. Cell Growth Differ 1991, 2:305-310.
13. Kaldis P., Russo A.A., Chou H.S., Pavletich N.P., Solomon M.J. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 1998, 9:2545-2560.
14. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
15. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66.
16. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6:387-400.
17. Lee M.H., Reynisdóttir I., Massagué J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995, 9:639-649.
18. Nilsson I., Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 2000, 4:107-114.
19. Dobashi Y. Cell cycle regulation and its aberrations in human lung carcinoma. Pathol Int 2005, 55:95-105.
20. Gautschi O., Ratschiller D., Gugger M., Betticher D.C., Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007, 55:1-14.
21. Wajed S.A., Laird P.W., DeMeester T.R. DNA methylation: an alternative pathway to cancer. Ann Surg 2001, 234:10-20.
22. Murphy J.A., Barrantes-Reynolds R., Kocherlakota R., Bond J.P., Greenblatt M.S. The CDKN2A database: integrating allelic variants with evolution, structure, function, and disease association. Hum Mutat 2004, 24:296-304.
23. Volm M., Koomägi R., Mattern J., Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 1997, 75:1774-1778.
24. Volm M., Koomägi R., Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 1998, 79:294-299.
25. Müller-Tidow C., Metzger R., Kügler K., Diederichs S., Idos G., Thomas M., et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001, 61:647-653.
26. Nakata S., Sugio K., Uramoto H., Oyama T., Hanagiri T., Morita M., et al. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006, 106:2190-2199.
27. Hirabayashi H., Ohta M., Tanaka H., Sakaguchi M., Fujii Y., Miyoshi S., et al. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53. J Surg Oncol 2002, 81:177-184.
28. Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002, 19:134-140.
29. Esposito V., Baldi A., Tonini G., Vincenzi B., Santini M., Ambrogi V., et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004, 57:58-63.
30. Zhu C.Q., Shih W., Ling C.H., Tsao M.S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006, 59:790-800.
31. Sathyan K.M., Nalinakumari K.R., Abraham T., Kannan S. CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma. Oral Oncol 2008, 44:689-697.
32. González P., Díez-Juan A., Coto E., Alvarez V., Reguero J.R., Batalla A., et al. A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biol 2004, 2:5.
33. Azzato E.M., Driver K.E., Lesueur F., Shah M., Greenberg D., Easton D.F., et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res 2008, 10:R47.
34. Song H., Hogdall E., Ramus S.J., Dicioccio R.A., Hogdall C., Quaye L., et al. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 2008, 14:1090-1095.
35. Chen J., Li D., Killary A.M., Sen S., Amos C.I., Evans D.B., et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol 2009, 16:431-439.
36. Zhang M., Hu Z., Huang J., Shu Y., Dai J., Jin G., et al. A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010, 16(February (4)):1236-1244.
37. Hu Z., Wang H., Shao M., Jin G., Sun W., Wang Y., et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum Mutat 2007, 28:431-440.
38. Cánepa E.T., Scassa M.E., Ceruti J.M., Marazita M.C., Carcagno A.L., Sirkin P.F., et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007, 59:419-426.
39. Bai F., Pei X.H., Godfrey V.L., Xiong Y. Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol 2003, 23:1269-1277.
40. Solomon D.A., Kim J.S., Jenkins S., Ressom H., Huang M., Coppa N., et al. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 2008, 68:2564-2569.
41. Leone P.E., Walker B.A., Jenner M.W., Chiecchio L., Dagrada G., Protheroe R.K., et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008, 14:6033-6041.
42. Sánchez-Aguilera A., Delgado J., Camacho F.I., Sánchez-Beato M., Sánchez L., Montalbán C., et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 2004, 103:2351-2357.
43. Uziel T., Zindy F., Xie S., Lee Y., Forget A., Magdaleno S., et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005, 19:2656-2667.
44. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
45. Delavaine L., La Thangue N.B. Control of E2F activity by p21Waf1/Cip1. Oncogene 1999, 18:5381-5392.
46. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002, 179:1-14.
47. Moldovan G.L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell 2007, 129:665-679.
48. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414.
49. Shih C.M., Lin P.T., Wang H.C., Huang W.C., Wang Y.C. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 2000, 91:9-15.
50. Yoshiya G., Takahata T., Hanada N., Suzuki K., Ishiguro A., Saito M., et al. Influence of cancer-related gene polymorphisms on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2008, 23:948-953.
51. Sauroja I., Smeds J., Vlaykova T., Kumar R., Talve L., Hahka-Kemppinen M., et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000, 28:404-414.